What are the key takeaways from this Odd Lots episode?

Key insights include: **Success probability management:** Biotech drugs have only five percent probability of FDA approval from initial concept, versus ten percent for biologics. Investors must build portfolios managing these low-probability, high-value outcomes where individual wins reach billions but take minimum ten years to materialize.; **Clinical trial bottleneck:** AI can generate more drug candidates, but the industry already drowns in good ideas. The real constraint is testing safety and efficacy on humans, costing thirty to forty million dollars per clinical program with no substitute for human trials currently available.; **China's structural advantages:** Chinese biotech benefits from faster regulatory approvals, lower clinical trial costs, higher volume capacity, and repatriated talent educated in US graduate schools. Recent trials replicated in Europe confirm Chinese data quality, making China the likely dominant force over the next decade.

What did D.a. Wallach discuss on Odd Lots?

DA Wallach explains why biotech venture capital differs fundamentally from tech investing, with five percent drug success rates, decade-long timelines, clinical trial bottlenecks, and China's emerging competitive advantages in regulatory speed and infrastructure. Key topics include: **Success probability management:** Biotech drugs have only five percent probability of FDA approval from initial concept, versus ten percent for biologics. Investors must build portfolios managing these low-probability, high-value outcomes where individual wins reach billions but take minimum ten years to materialize.; **Clinical trial bottleneck:** AI can generate more drug candidates, but the industry already drowns in good ideas. The real constraint is testing safety and efficacy on humans, costing thirty to forty million dollars per clinical program with no substitute for human trials currently available..

How long is this episode of Odd Lots?

This episode is 50 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Odd Lots

D.A. Wallach Explains Why Biotech VC Is So Different

December 12, 2025

50 min episode · 2 min read

D.a. Wallach

Episode

50 min

Read time

2 min

Topics

Investing, Startups, Fundraising & VC

AI-Generated Summary

Published Dec 22, 2025

Key Takeaways

✓Success probability management: Biotech drugs have only five percent probability of FDA approval from initial concept, versus ten percent for biologics. Investors must build portfolios managing these low-probability, high-value outcomes where individual wins reach billions but take minimum ten years to materialize.
✓Clinical trial bottleneck: AI can generate more drug candidates, but the industry already drowns in good ideas. The real constraint is testing safety and efficacy on humans, costing thirty to forty million dollars per clinical program with no substitute for human trials currently available.
✓China's structural advantages: Chinese biotech benefits from faster regulatory approvals, lower clinical trial costs, higher volume capacity, and repatriated talent educated in US graduate schools. Recent trials replicated in Europe confirm Chinese data quality, making China the likely dominant force over the next decade.
✓Gray hair premium: Biotech values experienced founders over young talent because clinical programs require thirty to forty million dollar commitments with no easy pivots. Each failure teaches irreplaceable lessons about navigating the translation from academic concepts to marketable products through specialized expertise.

What It Covers

DA Wallach explains why biotech venture capital differs fundamentally from tech investing, with five percent drug success rates, decade-long timelines, clinical trial bottlenecks, and China's emerging competitive advantages in regulatory speed and infrastructure.

Key Questions Answered

•Success probability management: Biotech drugs have only five percent probability of FDA approval from initial concept, versus ten percent for biologics. Investors must build portfolios managing these low-probability, high-value outcomes where individual wins reach billions but take minimum ten years to materialize.
•Clinical trial bottleneck: AI can generate more drug candidates, but the industry already drowns in good ideas. The real constraint is testing safety and efficacy on humans, costing thirty to forty million dollars per clinical program with no substitute for human trials currently available.
•China's structural advantages: Chinese biotech benefits from faster regulatory approvals, lower clinical trial costs, higher volume capacity, and repatriated talent educated in US graduate schools. Recent trials replicated in Europe confirm Chinese data quality, making China the likely dominant force over the next decade.
•Gray hair premium: Biotech values experienced founders over young talent because clinical programs require thirty to forty million dollar commitments with no easy pivots. Each failure teaches irreplaceable lessons about navigating the translation from academic concepts to marketable products through specialized expertise.

Notable Moment

Wallach challenges AI hype by noting that even if someone invented a model doubling drug success rates from five to ten percent, proving that improvement would require spending thirty billion dollars developing candidates before statistical validation becomes possible.

Know someone who'd find this useful?